Acute Coronary Syndrome Admission Order Set
Rapid bedside-ready admission orders for STEMI and NSTEMI: dual antiplatelet loading, anticoagulation selection, GDMT initiation, troponin trending, and cath lab activation criteria.
Acute coronary syndrome (ACS) spans STEMI, NSTEMI, and unstable angina (UA) — a continuum driven by plaque rupture, platelet aggregation, and partial-to-complete coronary occlusion. STEMI demands immediate reperfusion (door-to-balloon ≤90 min for primary PCI, door-to-needle ≤30 min for fibrinolysis); NSTEMI/UA stratifies to early invasive (≤24 h for high-risk), delayed invasive (25–72 h for intermediate risk), or ischemia-guided strategy. The admission order set must execute four parallel workstreams within the first hour: simultaneous DAPT loading, parenteral anticoagulation, guideline-directed medical therapy (GDMT) initiation (high-intensity statin, beta-blocker, ACE-I), and continuous monitoring with serial troponins. This protocol applies to type 1 MI presenting to the ED or telemetry floor; ICU transfer is required for hemodynamic instability, arrhythmia, mechanical complications, or cardiogenic shock (Killip ≥III).
S1. Triage, Activation, and Risk Stratification
The first 10 minutes determine outcome. ECG within 10 minutes of arrival defines the STEMI vs NSTEMI pathway. Continuous cardiac telemetry, defibrillator pads applied, two large-bore IVs, and bedside troponin assay must occur in parallel — never sequentially.
STEMI Activation Criteria
- ST-elevation ≥1 mm in 2 contiguous limb leads, ≥2 mm in V2–V3 (men <40), ≥2.5 mm V2–V3 (men ≥40), ≥1.5 mm V2–V3 (women)
- New LBBB with high clinical suspicion (Sgarbossa criteria)
- Posterior STEMI: ST-depression V1–V3 + tall R waves → obtain V7–V9 (≥0.5 mm elevation = STEMI)
- de Winter T-waves, Wellens syndrome, aVR elevation → STEMI equivalents, activate cath lab
⚡ Cath Lab Activation
Single-call activation by ED physician. Do not wait for cardiology consult, troponin result, or echo. Goal door-to-balloon ≤90 min (PCI-capable) or door-in-door-out ≤30 min for transfer; fibrinolysis only if anticipated PCI delay >120 min and no contraindications.
NSTEMI/UA Risk Stratification
Use HEART score (ED, screening) and GRACE 2.0 or TIMI (admitted, prognosis):
| Risk Tier | GRACE | TIMI | Strategy | Cath Timing |
|---|---|---|---|---|
| Very high | — | — | Hemodynamic instability, refractory angina, life-threatening arrhythmia, mechanical complication, acute HF | Immediate (<2 h) |
| High | >140 | ≥5 | Rising troponin, dynamic ST changes, GRACE >140 | Early (<24 h) |
| Intermediate | 109–140 | 3–4 | Diabetes, CKD, LVEF <40%, prior PCI/CABG | Delayed (25–72 h) |
| Low | <109 | 0–2 | Negative troponins, no recurrent symptoms | Ischemia-guided (stress test pre-discharge) |
S2. Dual Antiplatelet Therapy (DAPT) Loading
Load DAPT immediately upon ACS diagnosis, regardless of reperfusion strategy. Aspirin is universal; P2Y12 inhibitor selection depends on bleeding risk, anticipated CABG, and drug interactions. Pretreatment with P2Y12 inhibitor before cath is favored for STEMI; for NSTEMI, current ESC 2023 guidance discourages routine pretreatment when early invasive (<24 h) is planned and anatomy unknown.
Aspirin (Universal)
- Aspirin 162–325 mg PO chewed × 1 at first ACS contact (non-enteric coated for fastest absorption)
- Aspirin 81 mg PO daily indefinitely (per ADAPTABLE/CURRENT-OASIS 7: 81 mg = 325 mg efficacy, less GI bleeding)
- If true aspirin allergy or GI intolerance: desensitize if PCI planned, or substitute clopidogrel monotherapy (less ideal)
P2Y12 Inhibitor Selection
| Drug | Loading | Maintenance | Onset | Notes |
|---|---|---|---|---|
| Ticagrelor (Brilinta) | 180 mg PO × 1 | 90 mg PO BID | 30 min | Preferred (PLATO). Reversible. Dyspnea ~14%. Avoid with CYP3A4 strong inhibitors. Hold 5 d pre-CABG. |
| Prasugrel (Effient) | 60 mg PO × 1 | 10 mg PO daily (5 mg if ≥75 y or <60 kg) | 30 min | STEMI/PCI preferred. Contraindicated: prior stroke/TIA. Hold 7 d pre-CABG. |
| Clopidogrel (Plavix) | 600 mg PO × 1 (PCI); 300 mg (fibrinolysis ≤75 y, none >75 y) | 75 mg PO daily | 2–6 h | Use if ticagrelor/prasugrel contraindicated or unaffordable. CYP2C19 LOF reduces efficacy. |
| Cangrelor (Kengreal) | 30 mcg/kg IV bolus | 4 mcg/kg/min IV × 2 h or end of PCI | 2 min | For PCI when oral P2Y12 not feasible (NPO, intubated). Bridge to oral within 1 h of stop. |
⚠ DAPT Selection Pitfalls
- Prasugrel: Black-box contraindication for prior stroke/TIA — confirm history before loading
- Ticagrelor: Avoid concurrent strong CYP3A4 inhibitors (ketoconazole, ritonavir) and inducers (rifampin, phenytoin); aspirin maintenance must be ≤100 mg (high-dose ASA reduces ticagrelor benefit)
- Anticipated CABG within 5–7 days: prefer cangrelor or short-acting alternative; do not load long-acting P2Y12
- Renal failure (eGFR <30): ticagrelor and prasugrel do not require dose adjustment; clopidogrel preferred for end-stage renal disease (HEMO data)
S3. Parenteral Anticoagulation
Anticoagulation is given concurrently with DAPT. Selection depends on STEMI vs NSTEMI, primary PCI vs fibrinolysis vs medical management, and bleeding/renal profile. Continue until end of PCI (UFH/bivalirudin) or until discharge/8 days (enoxaparin/fondaparinux for NSTEMI medical management).
| Drug | STEMI Primary PCI | STEMI Fibrinolysis | NSTEMI | Notes |
|---|---|---|---|---|
| UFH | 70–100 U/kg IV bolus (50–70 if GP IIb/IIIa); titrate ACT 250–300 (HemoTec) | 60 U/kg bolus (max 4000) + 12 U/kg/hr (max 1000/hr); aPTT 1.5–2× control × 48 h | 60 U/kg bolus + 12 U/kg/hr; aPTT q6h | First-line in PCI; reversible with protamine. HIT risk after 5 d. |
| Enoxaparin | 0.5 mg/kg IV bolus (with PCI) | 30 mg IV bolus + 1 mg/kg SC q12h (<75 y); no bolus + 0.75 mg/kg q12h (≥75 y); CrCl <30: q24h | 1 mg/kg SC q12h; no bolus needed; CrCl <30: 1 mg/kg q24h | Reduces ischemic events vs UFH in fibrinolysis (ExTRACT-TIMI 25). Crossover with UFH increases bleeding. |
| Bivalirudin | 0.75 mg/kg IV bolus + 1.75 mg/kg/hr during PCI; consider continuing 4 h post-PCI | Not used | Alternative to UFH if HIT or high bleeding risk | Less major bleeding than UFH+GP IIb/IIIa (HORIZONS-AMI); slight stent thrombosis risk in early hours. |
| Fondaparinux | Avoid (catheter thrombosis risk) | 2.5 mg IV bolus → 2.5 mg SC daily × 8 d or to discharge | 2.5 mg SC daily × 8 d or to discharge | Lowest bleeding risk for medical management (OASIS-5). Not for primary PCI without UFH co-administration. |
ℹ Fibrinolytic Choice
If primary PCI not feasible within 120 min and no contraindications, give within 30 min of arrival:
- Tenecteplase (TNK): single weight-based bolus (<60 kg: 30 mg; 60–69: 35 mg; 70–79: 40 mg; 80–89: 45 mg; ≥90: 50 mg). Half-dose for ≥75 y per STREAM trial.
- Alteplase (tPA): 15 mg bolus → 0.75 mg/kg over 30 min (max 50 mg) → 0.5 mg/kg over 60 min (max 35 mg); total ≤100 mg.
- Pharmaco-invasive strategy: transfer to PCI center within 2–24 h (cath even if reperfusion successful by ECG).
Fibrinolytic Contraindications
| Absolute | Relative |
|---|---|
| Prior intracranial hemorrhage (any time) | Severe uncontrolled HTN (SBP >180 / DBP >110) |
| Known intracranial neoplasm or AVM | Ischemic stroke >3 mo, dementia, intracranial pathology |
| Ischemic stroke within 3 mo (except acute <3 h) | Major surgery within 3 wk |
| Suspected aortic dissection | Recent internal bleeding (2–4 wk) |
| Active bleeding or bleeding diathesis (excludes menses) | Pregnancy |
| Significant closed-head/facial trauma within 3 mo | Active peptic ulcer; current oral anticoagulant therapy (INR >2) |
S4. GDMT Initiation Within 24 Hours
Guideline-directed medical therapy reduces 30-day and 1-year mortality. Initiate within the first 24 h unless contraindicated; titrate to target dose during hospitalization and outpatient follow-up.
High-Intensity Statin (Day 1)
- Atorvastatin 80 mg PO daily (preferred; PROVE-IT, MIRACL evidence) — initiate within 24 h regardless of baseline LDL
- Rosuvastatin 20–40 mg PO daily (alternative)
- Goal LDL <55 mg/dL (very-high-risk per ESC 2019/2023; ACC/AHA: <70 mg/dL)
- Add ezetimibe 10 mg PO daily if LDL not at goal at 4–6 wk; PCSK9 inhibitor (evolocumab/alirocumab) as third-line
- Check baseline ALT, CK; recheck lipid panel 4–6 wk post-discharge
Beta-Blocker (Within 24 h if Stable)
- Metoprolol tartrate 25–50 mg PO BID (titrate to HR 55–70, then convert to metoprolol succinate 25–200 mg daily for outpatient)
- Alternative: Carvedilol 6.25 mg PO BID → titrate to 25 mg BID (especially if EF <40%)
- Hold if: signs of acute HF (rales, S3, hypotension), 2nd/3rd degree AV block, HR <60, SBP <100, severe asthma/COPD with bronchospasm, cardiogenic shock, active cocaine use
- IV beta-blockade (e.g., metoprolol 5 mg IV q5min × 3) — only if persistent HTN/tachycardia and no HF; routine IV use NOT recommended (COMMIT trial increased shock risk)
ACE Inhibitor / ARB (Within 24 h)
- Lisinopril 2.5–5 mg PO daily, titrate to 10–40 mg daily — esp. if anterior MI, EF <40%, HF, diabetes, HTN, CKD
- Alternative: Captopril 6.25 mg PO TID (short-acting, easy titration in unstable patients)
- If ACE-I intolerant (cough, angioedema): Valsartan 40 mg PO BID → titrate to 160 mg BID
- Hold if: SBP <100, bilateral renal artery stenosis, hyperkalemia (K >5.0), AKI
- Monitor SCr, K+ at 1–2 weeks post-initiation
Mineralocorticoid Receptor Antagonist (MRA)
For post-MI EF ≤40% with diabetes or HF symptoms (EPHESUS trial):
- Eplerenone 25 mg PO daily → 50 mg daily; preferred over spironolactone (less gynecomastia)
- Hold if K >5.0 mEq/L or eGFR <30 (women <50, men <30 per labels). Recheck K+ at 48–72 h then weekly × 4 wk.
SGLT2 Inhibitor (Emerging)
- Consider Empagliflozin 10 mg PO daily or Dapagliflozin 10 mg PO daily for patients with HF, T2DM, or CKD (EMPACT-MI mortality benefit emerging)
- Hold if eGFR <20, type 1 DM, recurrent UTI/genital mycotic infection
Symptom Management
- Nitroglycerin SL 0.4 mg q5min × 3 for ongoing chest pain; then IV NTG 5–10 mcg/min titrated to pain (max 200 mcg/min)
- Hold nitrates if: SBP <90, HR <50, RV infarct (inferior STEMI with V4R elevation), PDE-5 inhibitor within 24–48 h
- Morphine 2–4 mg IV q5–15min for refractory pain — but use sparingly (CRUSADE registry: morphine ↑ mortality in NSTEMI; delays oral P2Y12 absorption)
- Supplemental O2 only if SpO2 <90% (AVOID trial: hyperoxia ↑ infarct size)
- Anxiolytics PRN (lorazepam 0.5–1 mg IV/PO) for refractory anxiety contributing to chest pain
✅ First 24-Hour GDMT Checklist
- Aspirin 81 mg PO daily ordered
- P2Y12 inhibitor (ticagrelor/prasugrel/clopidogrel) ordered
- Parenteral anticoagulation initiated
- High-intensity statin (atorvastatin 80 / rosuvastatin 40) ordered
- Beta-blocker (metoprolol/carvedilol) — or contraindication documented
- ACE-I/ARB — or contraindication documented
- Echo ordered (LVEF, RWMA, mechanical complications)
- Lipid panel, HbA1c, BNP/NT-proBNP, BMP, CBC, coags drawn
- Nicotine cessation counseling, cardiac rehab referral
- Follow-up cardiology appointment scheduled within 1–2 wk
S5. Monitoring, Labs, and Imaging
Continuous Monitoring
- Telemetry: minimum 24–48 h for uncomplicated NSTEMI, 48–72 h post-PCI, longer for STEMI with complications
- Defibrillator pads on at admission; ACLS at bedside
- Vital signs: q15min × 1 h, q30min × 4 h, q1h × 24 h, then q4h
- Strict I/O; daily weights
Serial Troponin Trending
- High-sensitivity troponin (hs-cTn): 0 h + 1 h (or 0 + 2 h) algorithm — rule-in if >URL × 5 with rise/fall, rule-out if <LOD with no chest pain
- Conventional troponin: 0 h, 3–6 h, 6–12 h × 3
- Peak troponin correlates with infarct size; routine peak measurement only for prognostication
Imaging
- Transthoracic echo: within 24–48 h — assess LVEF, regional wall motion, mechanical complications (papillary muscle rupture, VSD, free-wall rupture, pericardial effusion)
- Cardiac MRI: consider for ambiguous NSTEMI, MINOCA workup (myocarditis, takotsubo, embolic infarct)
- Coronary CTA: not routine acute; useful for low-risk chest pain rule-out in ED
Laboratory Workup
| Test | Timing | Purpose |
|---|---|---|
| hs-cTn | 0 h, 1 h (or 0, 3, 6 h) | Diagnose ACS, trend infarct |
| BMP, Mg, Phos | Admission, daily | Electrolytes (K+ >4, Mg >2), renal fxn pre-cath contrast |
| CBC + plt | Admission, daily × 3 | Bleeding, HIT (plt drop >50% on day 5–14 of heparin) |
| PT/INR, aPTT | Admission, q6h on UFH | Bleeding risk, anticoag titration |
| Lipid panel | Admission (within 24 h) | Baseline LDL for statin titration |
| HbA1c | Admission | Diabetes screen/control |
| BNP / NT-proBNP | Admission, repeat if HF | Prognosis, HF detection |
| TSH | Admission | Underlying thyroid disorder driving ACS |
| Urine tox | If suspected | Cocaine/methamphetamine MI |
📞 When to Escalate / Page Cardiology
- Hemodynamic instability: SBP <90 not responsive to fluid → ICU + inotrope/vasopressor; consider IABP, Impella, ECMO
- Sustained VT/VF: ACLS + amiodarone 150 mg IV → 1 mg/min × 6 h → 0.5 mg/min × 18 h; rule out reperfusion arrhythmia vs ongoing ischemia
- Mechanical complications: new harsh murmur, hypotension, pulmonary edema 2–7 d post-MI → emergent echo + cardiothoracic surgery
- Recurrent angina post-PCI: stent thrombosis until proven otherwise → emergent re-cath
- Cardiogenic shock (Killip IV, lactate >2, oliguria): SCAI shock stages B–E → MCS + revascularization
S6. Disposition and Special Populations
Disposition planning at ACS admission depends on revascularization timing, comorbidities, and bleeding risk. STEMI patients move directly to the cath lab with door-to-balloon target ≤90 minutes; intermediate-to-high risk NSTEMI patients require invasive strategy within 2-24 hours depending on risk stratification. Low-risk NSTEMI patients without ongoing ischemia may have a delayed invasive approach within 72 hours, particularly when bleeding risk is high. Post-cath disposition: CCU for hemodynamic instability, arrhythmia, or high bleed risk; step-down for stable post-PCI; ward for low-risk post-medical management. Routine ICU admission is no longer standard for uncomplicated STEMI post-PCI; selected step-down placement is reasonable.
Special populations require modified approaches. Elderly (>75 years) ACS patients have higher bleeding risk and benefit from clopidogrel rather than ticagrelor or prasugrel for DAPT, prasugrel is contraindicated above age 75 unless diabetes is present and weight is >60 kg. CKD patients require dose adjustment for renally cleared agents and consideration of bivalirudin instead of heparin in advanced renal failure. Patients on chronic anticoagulation (warfarin or DOAC for AF, VTE) need careful peri-PCI bridging — typically held without LMWH bridge for low-thrombotic-risk indications, with consideration of triple therapy (anticoagulant + clopidogrel + aspirin) for 1-3 months post-PCI followed by dual therapy. Cocaine-associated ACS gets benzodiazepines for sympathetic drive, nitroglycerin, calcium channel blockers — and avoid beta-blockers in acute presentation due to unopposed alpha-mediated vasoconstriction risk.
Level of Care
- CCU/ICU: STEMI <24 h post-PCI, hemodynamic instability, ongoing arrhythmia, mechanical complications, post-arrest, cardiogenic shock, IABP/Impella in place
- Step-down/telemetry: stable post-PCI 24–48 h, uncomplicated NSTEMI
- Floor/discharge: low-risk NSTEMI ruled out, negative troponins, ischemia-guided strategy
Anticoagulated Patient (Triple Therapy Dilemma)
- If chronic AF, mechanical valve, or VTE on warfarin/DOAC + ACS: triple therapy (DOAC + DAPT) for 1–4 weeks, then drop aspirin → DOAC + P2Y12 (clopidogrel preferred) until 12 months → DOAC alone
- AUGUSTUS trial: apixaban + clopidogrel ↓ bleeding vs warfarin + DAPT
- Use rivaroxaban 15 mg daily (PIONEER AF-PCI) or apixaban 5 mg BID with P2Y12
Renal Impairment
- Pre-cath: hold metformin, NSAIDs, ARB if AKI; isotonic IV fluid (0.9% NS 1 mL/kg/h × 12 h pre + 12 h post) for CIN prevention if eGFR <60
- Avoid GP IIb/IIIa (eptifibatide, tirofiban) if CrCl <30; reduce eptifibatide to 1 mcg/kg/min
- Enoxaparin q24h (not q12h) if CrCl <30; UFH preferred for ESRD/dialysis
Elderly (≥75 years)
- Prasugrel maintenance dose 5 mg (not 10 mg)
- Avoid prasugrel altogether if <60 kg or prior stroke/TIA
- Half-dose tenecteplase (STREAM)
- Lower bleeding threshold; CRUSADE bleeding score useful for risk stratification
Diabetes
- Hold metformin 24–48 h pre-contrast (lactic acidosis if CIN develops)
- Sliding-scale insulin or insulin drip; target glucose 140–180 mg/dL (DIGAMI 2 — strict control no benefit, ↑ hypoglycemia)
- SGLT2 inhibitor for cardiometabolic protection on discharge (EMPA-REG, CANVAS)
Cocaine-Induced ACS
- Avoid beta-blockers (unopposed α-stimulation → coronary vasospasm)
- Benzodiazepines first-line (lorazepam 1–2 mg IV)
- Nitrates, CCB (diltiazem 10 mg IV) for ongoing ischemia
- Aspirin + heparin standard; PCI if STEMI
S7. Pearls, Pitfalls, and FAQ
🎯 Clinical Pearl: posterior STEMI
ST-depression V1–V3 with tall R waves (R/S ratio >1 in V2) = posterior STEMI. Add posterior leads V7–V9; ≥0.5 mm ST-elevation confirms. Activate cath lab. Often missed because front leads show “depression” (mirror image) — treat as STEMI equivalent.
⚠ Pitfall: morphine in NSTEMI
Morphine slows gastric emptying, reduces P2Y12 absorption (CRUSADE registry: ↑ mortality), and can mask ischemic symptoms. Use only for refractory pain after nitrates. Prefer escalating nitrates and rapid revascularization over morphine to “control” pain.
🎯 Clinical Pearl: RV infarct + nitrates
Inferior STEMI with hypotension → suspect RV infarct. Get right-sided ECG (V4R ≥1 mm = RV STEMI). RV infarct is preload-dependent: avoid nitrates and morphine (will crash BP). Give IV fluid bolus 250–500 mL NS, dobutamine if needed; revascularize urgently.
⚠ Pitfall: beta-blockers in acute HF
Routine IV beta-blocker in acute STEMI ↑ cardiogenic shock (COMMIT). Hold beta-blocker if: rales, S3, JVD, SBP <100, HR <60, signs of low output. Initiate within 24 h ONLY when hemodynamically stable.
🎯 Clinical Pearl: MINOCA
5–10% of MI have non-obstructive coronaries (MINOCA). Consider takotsubo, myocarditis, embolic MI, vasospasm, SCAD (esp. young women postpartum). Cardiac MRI within 1–2 weeks; intracoronary imaging (OCT/IVUS) at index cath if clinically suspected to identify plaque rupture vs SCAD.
⚠ Pitfall: stopping DAPT early
DAPT minimum 12 months post-DES (per ACC/AHA), 6 months acceptable in selected lower-risk patients (per ESC 2023 with newer DES). Never stop DAPT for elective non-cardiac surgery within 6 months without cardiology input. Bridging with cangrelor or shortening to single P2Y12 inhibitor only with shared decision.
Ticagrelor and prasugrel are both preferred over clopidogrel for ACS. Choose ticagrelor when prior stroke/TIA history (prasugrel contraindicated), unknown coronary anatomy at admission, or NSTEMI without planned PCI. Choose prasugrel for STEMI patients undergoing PCI in whom anatomy is known and no stroke history exists — ISAR-REACT 5 favored prasugrel for STEMI/NSTEMI with known anatomy. Use clopidogrel when both are contraindicated, unaffordable, when patient is on chronic OAC (triple therapy), or after fibrinolysis (300 mg load if <75 y, no load if ≥75 y).
For STEMI with planned primary PCI, yes — load DAPT immediately. For NSTEMI, current ESC 2023 guidance does not recommend routine pretreatment when invasive strategy is planned within 24 hours and anatomy is unknown (ACCOAST trial showed no benefit and ↑ bleeding with prasugrel pretreatment). Pretreat if cath delayed beyond 24 h or if patient is being managed conservatively. For ticagrelor, ACC/AHA still permits pretreatment but ESC has shifted away.
Primary PCI is preferred whenever feasible. Fibrinolysis is given when anticipated PCI delay exceeds 120 minutes from first medical contact (door-to-balloon ≥120 min). Give within 30 minutes of arrival at non-PCI hospital (“door-to-needle ≤30 min”) if no contraindications. After fibrinolysis, transfer to PCI center for pharmaco-invasive strategy — cath within 2–24 hours regardless of clinical reperfusion status (CARESS-in-AMI, TRANSFER-AMI). Rescue PCI is mandatory if reperfusion fails (persistent ST-elevation >50% at 60–90 min, ongoing chest pain, hemodynamic instability).
Initial: hold OAC, give aspirin + P2Y12 + parenteral anticoagulation as standard. Post-PCI: triple therapy (OAC + aspirin + clopidogrel) for 1–4 weeks (shorter for high-bleed-risk per WOEST/AUGUSTUS), then drop aspirin → dual therapy (OAC + clopidogrel) until 12 months → OAC alone. Use clopidogrel (not ticagrelor or prasugrel) and prefer apixaban 5 mg BID or rivaroxaban 15 mg daily over warfarin per AUGUSTUS and PIONEER AF-PCI. Mechanical valves remain on warfarin (DOACs contraindicated).
Default: 12 months DAPT after ACS regardless of stent type (ACC/AHA). For very-high-bleeding-risk patients, ESC 2023 permits 1–3 months DAPT followed by P2Y12 monotherapy (or aspirin) — TWILIGHT and STOPDAPT-2 trials. For lower-bleeding-risk patients with high ischemic risk (recurrent MI, complex PCI, diabetes), prolonged DAPT >12 months is reasonable (PEGASUS-TIMI 54: ticagrelor 60 mg BID with aspirin reduces ischemic events). Use DAPT score or PRECISE-DAPT score to individualize. Always check medication tolerance, bleeding history, and planned procedures before extending or shortening.
the established Protocol Experience with ACS Admission Orders
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)An acute coronary syndrome admission set is copied forward at three in the morning by whoever is covering rather than by the interventionalist, and admission-order quality determines whether the patient gets timely guideline-directed therapy or suffers from default omissions. The two failure modes experienced clinicians see most often: under-using ticagrelor in favor of clopidogrel in younger patients without contraindications, and delaying GDMT initiation past 24 hours. Below is how they actually run these orders.
Ticagrelor First in Most Patients
In practice, ticagrelor 180 mg load + 90 mg BID maintenance is preferred over clopidogrel for ACS in patients without contraindications: age >75 (clopidogrel preferred for bleeding), prior intracranial hemorrhage (ticagrelor contraindicated), severe hepatic impairment, or known severe asthma/COPD (dyspnea side effect). The PLATO trial data favor ticagrelor on ischemic outcomes, and the dyspnea side effect is usually manageable. Clopidogrel reflex prescription wastes the better drug — seasoned clinicians default to ticagrelor and document the explicit reason for any clopidogrel choice.
GDMT Within 24 Hours, Not “Outpatient”
The reflex “we’ll start statin/ACEi/beta-blocker at discharge” misses the inpatient window where compliance is high and titration can be observed. In practice, high-intensity statin (atorvastatin 80 mg or rosuvastatin 40 mg), beta-blocker (metoprolol succinate 25 mg if hemodynamically stable, no acute heart failure), and ACEi (lisinopril 2.5-5 mg starting dose) all started within 24 hours of admission unless specific contraindications. The discharge medication review captures additions; the inpatient initiation captures tolerability and produces meaningful 30-day mortality benefit.
STEMI: Door-to-Balloon ≤90 Min, Cath Lab Direct
For STEMI, the metric that matters is door-to-balloon time ≤90 minutes — and the system that delivers it is direct ED-to-cath bypass, not “transfer to ICU then call cath team.” In practice, STEMI alert triggers parallel pathway: cath lab activation, ASA 325 + ticagrelor 180 mg load + heparin 70 units/kg bolus, transport to cath. Bedside echo not required pre-cath. The 30-90 minute timing window is where mortality differs; don’t waste 20 minutes on “complete workup before cath.”
CRUSADE Score Guides Invasive Strategy
The CRUSADE bleeding score informs invasive vs conservative strategy for NSTEMI. In experienced hands, NSTEMI patients with CRUSADE score in moderate-very-high range (≥40) get bivalirudin substitution for heparin pre-PCI (lower bleeding), radial access mandatory, shorter DAPT duration considered post-PCI. Low CRUSADE patients can get heparin/femoral access standard approach. The bleeding risk assessment is as important as ischemic risk; ignoring it produces preventable major bleeding in the high-bleed cohort.
A Case That Defined The GDMT Discipline
A man in his late 50s admitted with NSTEMI, troponin peak 12 ng/mL, EF 45% on initial echo, peak creatinine 1.4. The admitting team had loaded clopidogrel and heparin, but deferred beta-blocker and statin to “outpatient cardiology follow-up.” The treating clinicians revised orders on consult: switched DAPT to ticagrelor 180 mg load + 90 mg BID, started atorvastatin 80 mg + metoprolol succinate 25 mg + lisinopril 5 mg within hospital day 1. Post-PCI he continued GDMT with adequate tolerability; 30-day post-discharge follow-up confirmed all medications continued and titrated up to target doses. His 1-year LDL was 52, BP 122/78, no readmissions.
Practice Pattern Refinements Beyond the Standard Order Set
- Order set defaults: ticagrelor over clopidogrel. The ACS admission order template has ticagrelor 180 mg load + 90 mg BID as the default DAPT P2Y12 inhibitor, with clopidogrel as the alternative requiring explicit indication checkbox (age >75, prior ICH, etc.). The default selection drives the prescribing pattern toward the better agent.
- GDMT bundle order: statin + BB + ACEi all in first 24h. Single order set checkbox initiates atorvastatin 80 mg + metoprolol succinate 25 mg + lisinopril 5 mg with monitoring parameters specified. Contraindications addressed by alternative selections (HF on admission → defer BB until stable; AKI → defer ACEi). The bundle approach captures all three rather than relying on individual orders that may be omitted.
- CRUSADE score documented at admission for every NSTEMI. Calculated and recorded in the admission note; drives invasive vs conservative strategy and DAPT duration decisions. The score is brief (8 variables) and high-yield for bleed-risk awareness.
- Smoking cessation prescribed as part of discharge bundle. Nicotine replacement therapy + behavioral counseling + varenicline if needed — not “we’ll discuss at follow-up.” The post-MI smoking cessation produces meaningful mortality benefit and the admission is the highest-motivation moment for the patient. Discharge plan includes follow-up phone calls at 2 and 4 weeks for sustained cessation support.
- Acute Pancreatitis Admission Order Set: Fluids, Pain, Nutrition, and Severity-Based Escalation
- Acute Decompensated Heart Failure (ADHF) Admission Order Set — Diuresis, Vasodilator, and Monitoring Protocol
- Acute Variceal Hemorrhage Admission Order Set: Resuscitation, Vasoactive, Antibiotic, and Endoscopy Bundle
- Severe Alcoholic Hepatitis Admission Order Set
- Hepatic Encephalopathy Admission Order Set: AASLD Lactulose Rifaximin Ammonia Workup and Precipitant Reversal
- Severe Ulcerative Colitis Flare Admission Order Set